Use of Nonlinear Mixed Effects Modelling in the Development of in Vitro-in Vivo Correlations
The variability associated with the estimation of the pharmacokinetic and pharmacodynamic parameters of a population has traditionally been described using simple statistical terms such as the mean and standard deviation. Other sources of variability exist within the population, such as the quantitative relationship of the parameter to individual physiology (such as weight, age, kidney function), the magnitude of the intersubject variability across the population and the magnitude of the residual deviations between the predicted and observed drug concentrations within a subject1,2.
KeywordsCumulative Amount Akaike Information Criterion Intersubject Variability Nonlinear Mixed Effect Nonlinear Mixed Effect Modelling
Unable to display preview. Download preview PDF.
- 5.Beal SL and Sheiner LB. NONMEM Users guides, NONMEM Project Group, UCSF, San Francisco, CA, 1992.Google Scholar
- 6.In vitro-in vivo correlations. Pharmacopeial Forum USP 1993;19:5374-9.Google Scholar
- 7.‘Draft guidance for industry: modified release solid dosage forms; scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation. U.S. Department of Health and Human Services, Food and Drug Administration, July 1996.Google Scholar
- 11.Gillespie WR, Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the “gastrointestinal bioavailability” and mean in vivo dissolution time of some ibuprofen dosage forms. J Pharmacokinet Biopharm 1985;13: 289–307.Google Scholar
- 12.Gillespie WR. PCDCON: Deconvolution for pharmacokinetic applications. University of Texas at Austin, Austin TX. 1992Google Scholar
- 13.ADAPT II. D’Argenio D. Biomedical Simulations Resource, USC, CA.Google Scholar